Abstract
Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Current Cancer Therapy Reviews
Title: Update on the Rheumatologic Manifestations of Malignancy
Volume: 3 Issue: 3
Author(s): Lianne Marks, Clifton D. Fuller, Parag Sanghvi, Melva Pinn and Charles R. Thomas
Affiliation:
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Abstract: Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Export Options
About this article
Cite this article as:
Lianne Marks , Clifton D. Fuller , Parag Sanghvi , Melva Pinn and Charles R. Thomas , Update on the Rheumatologic Manifestations of Malignancy, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368378
DOI https://dx.doi.org/10.2174/157339407781368378 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Agents Against COVID-19 with Clinical Evidence
Current Pharmaceutical Design Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Development of Infection and Inflammation Targeting Compounds
Current Radiopharmaceuticals Inflammation, Adipocytokines, and Atherosclerosis in the Metabolic Syndrome
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Comparison of <i>In Vitro</i> and <i>In Vivo</i> Effects of Infliximab on Cytokine Production in Proliferating CD4+ T Cells in Patients with Rheumatoid Arthritis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling
Current Medicinal Chemistry Anti-apoptotic Serpins as Therapeutics in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Natural and Synthetic Inhibitors of Caspases: Targets for Novel Drugs
Current Drug Targets - CNS & Neurological Disorders Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Catheter Related Line Sepsis Resulting from Mycobacterium <i>chelonae</i> Infection in an Immunocompromised Host
Infectious Disorders - Drug Targets Utility of Measuring Serum Concentrations of Anti-TNF Agents and Anti-Drug Antibodies in Inflammatory Bowel Disease
Current Drug Metabolism ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Transformation of Benzo[b]thiophene-2, 3-diones to Functionalised Diaryldisulfides
Letters in Organic Chemistry The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Inflammation, High Density Lipoprotein and Endothelium
Current Medicinal Chemistry